


Substitute for forms 1449A/PTO & 1449B/PTO	ATTORNEY'S DKT NO. 032942-032	APPLICATION NO. 09/892,636
SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Malcolm KING et al	FILING DATE June 28, 2001
		GROUP 1623

AUG 8 5 2003



U.S. PATENT DOCUMENTS

RECEIVED

AUG 08 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Wei Feng, et al, "Improved Clearability of Cystic Fibrosis Sputum with Dextran Treatment <i>in vitro</i> ," American Journal of Respiratory and Critical Care Medicine, Vol. 157, 1998, pp. 710-714.
	W. Feng, et al, "Improved Clearability of Cystic Fibrosis Spectrum with Dextran Treatment <i>in vitro</i> ," Clin. Invest. Med., Vol. 20, No. 4 suppl., 1997, pp. S99.

Examiner Signature		Date Considered	10/30/03
-----------------------	---	--------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.